A four in one nanoplatform: Theranostic bismuth-containing nanoMOFs for chemo-photodynamic- radiation therapy and CT scan imaging.

IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY International Journal of Pharmaceutics Pub Date : 2024-11-18 DOI:10.1016/j.ijpharm.2024.124971
Naeimeh Hassanzadeh Goji, Mona Alibolandi, Mohammad Ramezani, Amir Sh Saljooghi, Mahdieh Dayyani, Sirous Nekooei
{"title":"A four in one nanoplatform: Theranostic bismuth-containing nanoMOFs for chemo-photodynamic- radiation therapy and CT scan imaging.","authors":"Naeimeh Hassanzadeh Goji, Mona Alibolandi, Mohammad Ramezani, Amir Sh Saljooghi, Mahdieh Dayyani, Sirous Nekooei","doi":"10.1016/j.ijpharm.2024.124971","DOIUrl":null,"url":null,"abstract":"<p><p>Integration of different therapeutic performances into one platform is an innovative development for using multiple applications in real-time. In this paper, for the first time we exploited the concurrent capacity of radio and photosensitizing in a theranostic nanoMOFs based on bismuth, zirconium, and porphyrin. The porosity of nanoMOFs provided the capability of doxorubicin loading and chemotherapy besides enhanced photodynamic and radiation therapy (PDT & RT). Its PEGylation and aptamer (MUC1) immobilization endowed the platform with high biocompatibility and targeted tumor killing, respectively. In vitro assay exhibited that this aptamer immobilized DOX-loaded PEGylated MOF (Apt@DOX) produced more toxicity against 4 T1 cells compared to non-targeted nanoparticles (NP@DOX), especially when the treatment combined with PDT or/and RT. In vivo experiment also provided great results for tumor growth, survival rate, and body weight for 4 T1 bearing mice injected by Apt@DOX in combination with irradiation by 660 nm laser and/or exposure to 3 Gy dosage of X-ray radiation. The CT imaging of injected mice with targeted and non-targeted bismuth-based MOF introduced this nanoplatform as a promising CT contrast agent. Resultantly, we can present our as-synthesized nanoplatform as an efficient multifunctional theranostics with the ability of multimodal therapy and diagnostic performance.</p>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":" ","pages":"124971"},"PeriodicalIF":5.3000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijpharm.2024.124971","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Integration of different therapeutic performances into one platform is an innovative development for using multiple applications in real-time. In this paper, for the first time we exploited the concurrent capacity of radio and photosensitizing in a theranostic nanoMOFs based on bismuth, zirconium, and porphyrin. The porosity of nanoMOFs provided the capability of doxorubicin loading and chemotherapy besides enhanced photodynamic and radiation therapy (PDT & RT). Its PEGylation and aptamer (MUC1) immobilization endowed the platform with high biocompatibility and targeted tumor killing, respectively. In vitro assay exhibited that this aptamer immobilized DOX-loaded PEGylated MOF (Apt@DOX) produced more toxicity against 4 T1 cells compared to non-targeted nanoparticles (NP@DOX), especially when the treatment combined with PDT or/and RT. In vivo experiment also provided great results for tumor growth, survival rate, and body weight for 4 T1 bearing mice injected by Apt@DOX in combination with irradiation by 660 nm laser and/or exposure to 3 Gy dosage of X-ray radiation. The CT imaging of injected mice with targeted and non-targeted bismuth-based MOF introduced this nanoplatform as a promising CT contrast agent. Resultantly, we can present our as-synthesized nanoplatform as an efficient multifunctional theranostics with the ability of multimodal therapy and diagnostic performance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
四合一纳米平台:用于化学-光动力-放射治疗和 CT 扫描成像的 Theranostic 含铋纳米MOFs。
将不同的治疗性能整合到一个平台中是一种创新发展,可用于多种实时应用。在本文中,我们首次在基于铋、锆和卟啉的治疗纳米MOFs 中同时利用了放射和光敏能力。除了增强光动力疗法和放射疗法(PDT 和 RT)外,纳米MOFs 的多孔性还提供了负载多柔比星和化疗的能力。其 PEG 化和适配体(MUC1)固定分别赋予了该平台高度的生物相容性和靶向肿瘤杀伤力。体外实验结果表明,与非靶向纳米颗粒(NP@DOX)相比,这种固定了多氧自由基(DOX)的 PEG 化 MOF(Apt@DOX)对 4 T1 细胞的毒性更大,尤其是在与局部放疗(PDT)或/和热疗(RT)联合治疗时。在体内实验中,使用 Apt@DOX 结合 660 纳米激光照射和/或 3 Gy 剂量 X 射线照射的 4 T1 携带小鼠的肿瘤生长、存活率和体重也得到了很好的结果。对注射了靶向和非靶向铋基 MOF 的小鼠进行的 CT 成像显示,该纳米平台是一种很有前景的 CT 造影剂。因此,我们所合成的纳米平台是一种高效的多功能治疗剂,具有多模式治疗和诊断性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.70
自引率
8.60%
发文量
951
审稿时长
72 days
期刊介绍: The International Journal of Pharmaceutics is the third most cited journal in the "Pharmacy & Pharmacology" category out of 366 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.
期刊最新文献
Liposomes-mediated enhanced antitumor effect of docetaxel with BRD4-PROTAC as synergist for breast cancer chemotherapy/immunotherapy. A four in one nanoplatform: Theranostic bismuth-containing nanoMOFs for chemo-photodynamic- radiation therapy and CT scan imaging. Cyclodextrin complexation as a fruitful strategy for improving the performance of nebivolol delivery from solid lipid nanoparticles. Human and canine osteosarcoma cell lines: How do they react upon incubation with calcium phosphate-coated lipid nanoparticles carrying doxorubicin and curcumin? Machine learning strengthened formulation design of pharmaceutical suspensions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1